RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
THE LANCET. HAEMATOLOGY
Collezione AOU Città della Salute di Torino

Items : 31

Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X.

2025
AOU Città della Salute di Torino

Mina R; Mylin AK; Yokoyama H; Magen H; Alsdorf W; Minnema MC; Shune L; Isufi I; Harrison SJ; Shah UA; Schecter JM; Vogel M; Lendvai N; Gries KS; Katz EG; Slaughter A; Lonardi C; Gilbert J; Li Q; Deraedt W; Filho OC; Patel N; Florendo E; Karlin L; Weisel K;

Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2024 Nov;11(11):e830-e838. doi: 10.1016/S2352-3026(24)00241-2. Epub 2024 Sep 20.

2024
AOU Città della Salute di Torino

Russo D; Polverelli N; Bernardi S; Santarone S; Farina M; Borlenghi E; Onida F; Castagna L; Bramanti S; Carella AM; Sorasio R; Martino M; Alati C; Olivieri A; Beltrami G; Curti A; Vetro C; Leotta S; Mancini V; Terruzzi E; Bernardi M; Galieni P; Musto P; Cerretti R; Giaccone L; Skert C; Radici V; Vezzoli M; Calza S; et alii...

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2024 Jul;11(7):e499-e509. doi: 10.1016/S2352-3026(24)00143-1.

2024
AOU Alessandria
AOU Città della Salute di Torino

Della Starza I; Drandi D; Genuardi E; Ciabatti E; Bomben R; De Novi LA; Cavalli M; Guarini A; Grapulin L; Assanto GM; Annechini G; Tani M; Celli M; Mannina D; Mannarella C; Cencini E; Re F; Bigliardi S; Corradini P; Stelitano C; Tucci A; Perrone T; Gaidano G; Musuraca G; Bernuzzi P; Bolis SA; Zilioli VR; Rattotti S; Ferreri AJM; et alii...

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2023 Oct;10(10):e813-e824. doi: 10.1016/S2352-3026(23)00218-1.

2023
AOU Città della Salute di Torino

Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Kampfenkel T; Liu W; Wang J; Kosh M; Tran N; Carson R; Sonneveld P;

10-day decitabine versus 3?+?7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2023 Nov;10(11):e879-e889. doi: 10.1016/S2352-3026(23)00273-9.

2023
AOU Città della Salute di Torino

Lübbert M; Wijermans PW; Kicinski M; Chantepie S; Van der Velden WJFM; Noppeney R; Griškevi?ius L; Neubauer A; Crysandt M; Vrhovac R; Luppi M; Fuhrmann S; Audisio E; Candoni A; Legrand O; Foà R; Gaidano G; van Lammeren-Venema D; Posthuma EFM; Hoogendoorn M; Giraut A; Stevens-Kroef M; Jansen JH; de Graaf AO; Efficace F; Ammatuna E; Vilque JP; Wäsch R; Becker H; et alii...

Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. in The Lancet. Haematology / Lancet Haematol. 2022 May;9(5):e361-e373. doi: 10.1016/S2352-3026(22)00073-4.

2022
AOU Città della Salute di Torino

Stemler J; de Jonge N; Skoetz N; Sinkó J; Brüggemann RJ; Busca A; Ben-Ami R; Rá?il Z; Piechotta V; Lewis R; Cornely OA;

An integrated approach to cardioprotection in lymphomas. in The Lancet. Haematology / Lancet Haematol. 2022 Jun;9(6):e445-e454. doi: 10.1016/S2352-3026(22)00082-5. Epub 2022 May 2.

2022
AOU Città della Salute di Torino

Maraldo MV; Levis M; Andreis A; Armenian S; Bates J; Brady J; Ghigo A; Lyon AR; Manisty C; Ricardi U; Aznar MC; Filippi AR;

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9.

2022
AOU Città della Salute di Torino

Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legie? W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špi?ka I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;

Antibody-drug conjugates: when chemotherapy meets immuno-oncology. in The Lancet. Haematology / Lancet Haematol. 2021 Nov;8(11):e778-e779. doi: 10.1016/S2352-3026(21)00236-2. Epub 2021 Sep 13.

2021
AOU Città della Salute di Torino

Mina R; Gay F;

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. Epub 2021 Jan 18.

2021
AOU Città della Salute di Torino

Scaffidi L; Lunghi F; Betti S; Guglielmelli P; Loscocco GG; Mannarelli C; Cacciola E; Mora B; Cascavilla N; Patriarca A; Siragusa S; Rumi E; Musolino C; Rapezzi D; Caramella M; Carli G; Ricco A; Pane F; Benevolo G; Palandri F; Iurlo A; Bonifacio M; Ciceri F; Ghirardi A; Rossi E; Ferrari A; Carobbio A; Masciulli A; De Stefano V; et alii...

Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2021 Jan;8(1):e34-e44. doi: 10.1016/S2352-3026(20)30358-6. Epub 2020 Dec 22.

2021
AOU Alessandria
AOU Città della Salute di Torino

Vitolo U; Martelli M; Stelitano C; Ciccone G; Narni F; Casaroli I; Stefani PM; Puccini B; Benedetti F; Ferreri AJM; Molinari AL; Ballerini F; Arcaini L; Gomes da Silva M; Chiappella A; Zilioli VR; Balzarotti M; Stefoni V; Pagani C; Re A; Di Rocco A; Zanni M; Cavallo F; Mian M; Tavarozzi R; Ferrero S; Evangelista A; Ladetto M; Cortelazzo S; et alii...

MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5.

2021
AOU Città della Salute di Torino

Ferreri AJM; Doorduijn JK; Re A; Cabras MG; Smith J; Ilariucci F; Luppi M; Calimeri T; Cattaneo C; Khwaja J; Botto B; Cellini C; Nassi L; Linton K; McKay P; Olivieri J; Patti C; Re F; Fanni A; Singh V; Bromberg JEC; Cozens K; Gastaldi E; Bernardi M; Cascavilla N; Davies A; Fox CP; Frezzato M; Osborne W; et alii...

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. in The Lancet. Haematology / Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28.

2021
AOU Città della Salute di Torino

Ludwig H; Sonneveld P; Facon T; San-Miguel J; Avet-Loiseau H; Mohty M; Mateos MV; Moreau P; Cavo M; Pawlyn C; Zweegman S; Engelhardt M; Driessen C; Cook G; Dimopoulos MA; Gay F; Einsele H; Delforge M; Caers J; Weisel K; Jackson G; Garderet L; van de Donk N; Leleu X; Goldschmidt H; Beksac M; Nijhof I; Schreder M; Abildgaard N; et alii...

Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. in The Lancet. Haematology / Lancet Haematol. 2020 Sep;7(9):e649-e659. doi: 10.1016/S2352-3026(20)30208-8. Epub 2020 Aug 3.